Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marta Morante

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Biomolecules|November 11, 2022
Immune Checkpoint Inhibitors and RAS-ERK Pathway-Targeted Drugs as Combined Therapy for the Treatment of MelanomaMarta Morante, Atanasio Pandiella, Piero Crespo, et al.
Endocrine-Related Cancer|April 13, 2019
Regulators of the RAS-ERK pathway as therapeutic targets in thyroid cancerMiguel A Zaballos, Adrián Acuña-Ruiz, Marta Morante, et al.
Cellular and Molecular Life Sciences : CMLS|September 3, 2022
Inhibiting ERK dimerization ameliorates BRAF-driven anaplastic thyroid cancerMiguel A Zaballos, Adrián Acuña-Ruiz, Marta Morante, et al.
Science Signaling|July 18, 2023
ERK2 stimulates <i>MYC</i> transcription by anchoring CDK9 to the <i>MYC</i> promoter in a kinase activity-independent mannerLorena Agudo-Ibáñez, Marta Morante, Lucía García-Gutiérrez, et al.
Science Advances|February 15, 2023
Scaffold coupling: ERK activation by trans-phosphorylation across different scaffold protein speciesAna Martín-Vega, Laura Ruiz-Peinado, Rocío García-Gómez, et al.
Cancer Research|August 17, 2013
BRD4 sustains melanoma proliferation and represents a new target for epigenetic therapyMiguel F Segura, Bárbara Fontanals-Cirera, Avital Gaziel-Sovran, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Biomolecules|November 11, 2022
Immune Checkpoint Inhibitors and RAS-ERK Pathway-Targeted Drugs as Combined Therapy for the Treatment of MelanomaMarta Morante, Atanasio Pandiella, Piero Crespo, et al.
Endocrine-Related Cancer|April 13, 2019
Regulators of the RAS-ERK pathway as therapeutic targets in thyroid cancerMiguel A Zaballos, Adrián Acuña-Ruiz, Marta Morante, et al.
Cellular and Molecular Life Sciences : CMLS|September 3, 2022
Inhibiting ERK dimerization ameliorates BRAF-driven anaplastic thyroid cancerMiguel A Zaballos, Adrián Acuña-Ruiz, Marta Morante, et al.
Science Signaling|July 18, 2023
ERK2 stimulates <i>MYC</i> transcription by anchoring CDK9 to the <i>MYC</i> promoter in a kinase activity-independent mannerLorena Agudo-Ibáñez, Marta Morante, Lucía García-Gutiérrez, et al.
Science Advances|February 15, 2023
Scaffold coupling: ERK activation by trans-phosphorylation across different scaffold protein speciesAna Martín-Vega, Laura Ruiz-Peinado, Rocío García-Gómez, et al.
Cancer Research|August 17, 2013
BRD4 sustains melanoma proliferation and represents a new target for epigenetic therapyMiguel F Segura, Bárbara Fontanals-Cirera, Avital Gaziel-Sovran, et al.
Pageof 1